{"id":"sofosbuvir-sovaldi","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Sofosbuvir, Sovaldi","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:08:39.283220+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:08:45.120979+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sofosbuvir, Sovaldi","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:08:45.463534+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: RNA-directed RNA polymerase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:08:46.803212+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1259059/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:08:46.453621+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-28T00:08:45.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:08:48.161803+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT03520660","phase":"PHASE4","title":"People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2018-10-19","conditions":"Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases","enrollment":121},{"nctId":"NCT04075916","phase":"PHASE2","title":"A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-06-22","conditions":"End Stage Renal Disease","enrollment":201},{"nctId":"NCT06953479","phase":"PHASE4","title":"Implementing Low-Barrier HCV Treatment in a Jail Setting","status":"RECRUITING","sponsor":"Lifespan","startDate":"2025-06-11","conditions":"HEPATITIS C (HCV), Incarceration, Injection Drug Use","enrollment":40},{"nctId":"NCT05653232","phase":"NA","title":"Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-19","conditions":"HCV","enrollment":120},{"nctId":"NCT05140941","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy","status":"RECRUITING","sponsor":"Catherine Anne Chappell","startDate":"2022-04-04","conditions":"Hepatitis C, Chronic, Pregnancy; Infection","enrollment":100},{"nctId":"NCT03383419","phase":"PHASE2","title":"Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2018-03-20","conditions":"Heart Failure","enrollment":15},{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT07316842","phase":"","title":"SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center of target therapy","startDate":"2025-09-17","conditions":"Viral Hepatitis C","enrollment":30},{"nctId":"NCT03222531","phase":"PHASE2","title":"Expanding the Pool in Orthotopic Heart Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mary E. Keebler, MD","startDate":"2017-08-01","conditions":"Hepatitis C, Heart Transplant, Cardiac Transplant","enrollment":20},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT05992077","phase":"NA","title":"Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-08-07","conditions":"HCV Infection","enrollment":21000},{"nctId":"NCT05248919","phase":"NA","title":"Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2023-06-01","conditions":"Hepatitis C","enrollment":318},{"nctId":"NCT03809533","phase":"PHASE2","title":"The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amit D Tevar, MD","startDate":"2019-05-29","conditions":"Kidney Transplantation, Hepatitis C","enrollment":30},{"nctId":"NCT03819322","phase":"PHASE2","title":"The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients","status":"COMPLETED","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2019-08-15","conditions":"Liver Transplant, Hepatitis C","enrollment":73},{"nctId":"NCT03949764","phase":"PHASE4","title":"The Kentucky Viral Hepatitis Treatment Study","status":"COMPLETED","sponsor":"Jennifer Havens","startDate":"2019-09-23","conditions":"Hepatitis C, Opioid-Related Disorders, Injection Drug Use","enrollment":374},{"nctId":"NCT07098481","phase":"PHASE4","title":"Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-09-01","conditions":"Hepatitis C Virus Infection","enrollment":576},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT06159504","phase":"EARLY_PHASE1","title":"Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania","status":"RECRUITING","sponsor":"Médecins du Monde","startDate":"2024-10-03","conditions":"Hepatitis C, RDT","enrollment":3040},{"nctId":"NCT03987503","phase":"PHASE4","title":"The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-07-01","conditions":"Hepatitis C, Chronic","enrollment":87},{"nctId":"NCT03112044","phase":"EARLY_PHASE1","title":"Lung Transplant HCV, Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2017-09-19","conditions":"Lung Transplant Infection, Hepatitis C","enrollment":26},{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT04943588","phase":"","title":"Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-11-01","conditions":"Hepatitis C, Chronic","enrollment":25000},{"nctId":"NCT04885855","phase":"PHASE2, PHASE3","title":"8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Muhammad Radzi Abu Hassan","startDate":"2021-03-23","conditions":"Hepatitis C","enrollment":322},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT02262728","phase":"PHASE2","title":"An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-30","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT04382404","phase":"PHASE1","title":"Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir","status":"COMPLETED","sponsor":"Catherine Anne Chappell","startDate":"2020-10-22","conditions":"Hepatitis C, Chronic","enrollment":11},{"nctId":"NCT05717400","phase":"PHASE4","title":"Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-17","conditions":"Liver Cancer","enrollment":2},{"nctId":"NCT06533319","phase":"NA","title":"Hepatitis C Treatment in Idaho County Jails","status":"NOT_YET_RECRUITING","sponsor":"Eastern Idaho Public Health","startDate":"2024-08-01","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03627546","phase":"NA","title":"HCV Seek, Test and Rapid Treatment for Young PWID","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-09-18","conditions":"Hepatitis C, Drug Use","enrollment":39},{"nctId":"NCT06306300","phase":"PHASE4","title":"Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2022-07-04","conditions":"Hepatitis C","enrollment":30000},{"nctId":"NCT04468087","phase":"PHASE2, PHASE3","title":"Antiviral Agents Against COVID-19 Infection","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2021-02-15","conditions":"COVID-19","enrollment":256},{"nctId":"NCT06180590","phase":"","title":"The Efficacy of Vosevi in Treating DAA-experienced Patients","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Guangzhou Medical University","startDate":"2023-02-28","conditions":"Chronic Hepatitis C, Medication Reaction","enrollment":200},{"nctId":"NCT03981211","phase":"NA","title":"Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2021-02-12","conditions":"Hepatitis C, Liver Inflammation, Liver Cirrhoses","enrollment":60},{"nctId":"NCT03855917","phase":"PHASE4","title":"Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2020-02-11","conditions":"Hepatitis C","enrollment":30},{"nctId":"NCT03570112","phase":"","title":"Transmission of Chronic Hepatitis C in Pregnancy","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2018-06-08","conditions":"Hepatitis C, Pregnancy Complications, Vertical Disease Transmission","enrollment":40},{"nctId":"NCT02759861","phase":"PHASE4","title":"Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2016-08-01","conditions":"Genotype 1 Hepatitis C Virus","enrollment":16},{"nctId":"NCT05264558","phase":"PHASE4","title":"Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%","status":"COMPLETED","sponsor":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","startDate":"2022-07-25","conditions":"Hepatitis C","enrollment":606},{"nctId":"NCT05016609","phase":"PHASE4","title":"Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)","status":"UNKNOWN","sponsor":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","startDate":"2022-03-09","conditions":"Hepatitis C","enrollment":1800},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT03801707","phase":"PHASE2, PHASE3","title":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2019-03-22","conditions":"Kidney Transplant, Hepatitis C, HCV","enrollment":54},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT03903185","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-03-01","conditions":"Hepatitis C, Chronic, Hematologic Malignancy","enrollment":24},{"nctId":"NCT03118674","phase":"PHASE2","title":"Harvoni Treatment Porphyria Cutanea Tarda","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-09-06","conditions":"Porphyria Cutanea Tarda, Hepatitis C","enrollment":23},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03612973","phase":"NA","title":"Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Chronic Hepatitis c","enrollment":80},{"nctId":"NCT05895448","phase":"PHASE4","title":"Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics","status":"UNKNOWN","sponsor":"Center For Hepatitis C, Atlanta, GA","startDate":"2018-03-01","conditions":"Chronic Hepatitis C, People Who Inject Drugs","enrollment":125},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT05854511","phase":"PHASE3","title":"Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-06-05","conditions":"HCV","enrollment":30},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT03057847","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Elizabeth Krans, MD","startDate":"2018-01-30","conditions":"Hepatitis C, Chronic, Opioid-use Disorder","enrollment":32},{"nctId":"NCT03702218","phase":"EARLY_PHASE1","title":"Hepatitis C Positive Donor Into Hepatitis C Negative Recipients","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-07-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03625687","phase":"PHASE4","title":"Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-05","conditions":"Respiratory Failure, Hepatitis C","enrollment":19},{"nctId":"NCT02596880","phase":"PHASE3","title":"Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-09","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT04653818","phase":"PHASE4","title":"HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-10-05","conditions":"Hepatocellular Carcinoma, Hepatitis C, Neoplasm Recurrence","enrollment":84},{"nctId":"NCT02836925","phase":"PHASE2","title":"Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2016-03","conditions":"Indolent B-cell Lymphoma, Hepatitis C","enrollment":40},{"nctId":"NCT04353986","phase":"PHASE3","title":"PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-06-11","conditions":"HCV Infection, Beta Thalassemia Major","enrollment":24},{"nctId":"NCT03540212","phase":"PHASE2, PHASE3","title":"Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-12-10","conditions":"Chronic HCV Infection","enrollment":50},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT02510300","phase":"","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-10-21","conditions":"Hepatitis C Virus Infection","enrollment":461},{"nctId":"NCT03492112","phase":"NA","title":"A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-09-10","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT03377478","phase":"PHASE1","title":"Expanding the Pool in Lung Transplantation","status":"COMPLETED","sponsor":"Pablo Sanchez","startDate":"2019-07-30","conditions":"Hepatitis C, Lung Transplant","enrollment":10},{"nctId":"NCT02660905","phase":"PHASE3","title":"HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-04","conditions":"Human Immunodeficiency Virus, Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT05601518","phase":"","title":"Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2022-11-01","conditions":"Hepatitis C Infection","enrollment":450},{"nctId":"NCT04246723","phase":"PHASE2","title":"Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2019-05-06","conditions":"Chronic Hepatitis c Genotype 1","enrollment":85},{"nctId":"NCT03086044","phase":"PHASE4","title":"Transplanting Hepatitis C Positive Organs","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2017-03-01","conditions":"Hepatitis C, Awaiting Organ Transplant","enrollment":148},{"nctId":"NCT05503979","phase":"","title":"Elimination of Hepatitis C Virus Among Users of Substances","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2022-11-15","conditions":"Hepatitis C in Substance Users","enrollment":1000},{"nctId":"NCT04695769","phase":"PHASE4","title":"Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-21","conditions":"Chronic Hepatitis C","enrollment":281},{"nctId":"NCT04852614","phase":"","title":"Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-12-01","conditions":"Hepatitis C Virus Infection","enrollment":10},{"nctId":"NCT05474781","phase":"","title":"Eliminating HCV Infection Among PWUD","status":"UNKNOWN","sponsor":"Vancouver Infectious Diseases Centre","startDate":"2019-02-22","conditions":"Hepatitis C, Chronic, Drug Use","enrollment":300},{"nctId":"NCT03882307","phase":"EARLY_PHASE1","title":"Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT05467826","phase":"PHASE4","title":"Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT04561063","phase":"PHASE2","title":"COVID-19 Prophylaxis South Africa (COVER HCW)","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-08","conditions":"Covid19, SARS-CoV Infection","enrollment":1950},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT02939989","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-21","conditions":"Hepatitis C Virus Infection","enrollment":33},{"nctId":"NCT04112303","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-10-16","conditions":"Hepatitis C Virus Infection","enrollment":37},{"nctId":"NCT03776760","phase":"","title":"Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2019-05-28","conditions":"Hepatitis C, Hepatitis, Liver Diseases","enrollment":600},{"nctId":"NCT02745535","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-05","conditions":"Chronic Hepatitis C","enrollment":77},{"nctId":"NCT02573376","phase":"NA","title":"Antiviral Pharmacology and Adherence in Drug Users","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-11","conditions":"HEPATITIS C, Virus, Human Immunodeficiency","enrollment":73},{"nctId":"NCT02938013","phase":"PHASE4","title":"deLIVER: Direct Acting Antiviral Effects on the Liver","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-01","conditions":"HCV Coinfection, Liver Disease, HIV","enrollment":15},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT03706898","phase":"PHASE1","title":"Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-10-01","conditions":"HIV-1-infection, Hepatic Impairment","enrollment":36},{"nctId":"NCT02907996","phase":"","title":"Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-09-09","conditions":"Hepatitis C Virus","enrollment":2033},{"nctId":"NCT03158857","phase":"","title":"Hepatitis C Treatment Study in Myanmar","status":"WITHDRAWN","sponsor":"Myanmar Oxford Clinical Research Unit","startDate":"2022-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT05138523","phase":"","title":"Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)","status":"COMPLETED","sponsor":"Beker Laboratories","startDate":"2019-11-21","conditions":"Chronic Hepatitis c","enrollment":99},{"nctId":"NCT02951364","phase":"","title":"Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-12-05","conditions":"Hepatitis C Virus","enrollment":1081},{"nctId":"NCT02625909","phase":"PHASE3","title":"Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2017-03-09","conditions":"Hepatitis C","enrollment":222},{"nctId":"NCT03146741","phase":"PHASE1, PHASE2","title":"Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-16","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT03236506","phase":"PHASE2","title":"A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2018-01-19","conditions":"Hepatitis C","enrollment":129},{"nctId":"NCT05092074","phase":"","title":"Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-10-01","conditions":"Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment","enrollment":100},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT05091008","phase":"PHASE2","title":"Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children","status":"COMPLETED","sponsor":"Mansoura University Children Hospital","startDate":"2018-03-01","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT03042520","phase":"","title":"Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-08","conditions":"Liver Fibroses, HepatoCellular Carcinoma, Cryoglobulinemia","enrollment":200},{"nctId":"NCT02964091","phase":"PHASE4","title":"Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World","status":"COMPLETED","sponsor":"Partners in Health","startDate":"2016-10","conditions":"Chronic Hepatitis C","enrollment":300},{"nctId":"NCT03312023","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-01","conditions":"Hepatitis B","enrollment":21},{"nctId":"NCT02455167","phase":"PHASE3","title":"Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-05","conditions":"Hepatitis C","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1259059"},"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SOF"],"phase":"marketed","status":"active","brandName":"Sofosbuvir, Sovaldi","genericName":"Sofosbuvir, Sovaldi","companyName":"Tarek I. Hassanein, M.D., FACP, FAG, AGAF","companyId":"tarek-i-hassanein-m-d-facp-fag-agaf","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:08:48.161803+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}